ArticleEvidence-based complementary and alternative medicine : eCAM2022

An Open-Label Exploratory Clinical Trial Evaluating the Effects of GLS (Coptidis Rhizoma-Evodiae Fructus 2 : 1) on Fibroblast Growth Factor 21 in Patients with Nonalcoholic Fatty Liver Disease.

Yang Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.